Skip to main content
Premium Trial:

Request an Annual Quote

BioForce Nanosciences Receives $500K from Warrant Exercise

NEW YORK (GenomeWeb News) – BioForce Nanosciences Holdings said today that it has received $500,000 in proceeds from an unnamed institutional investor that exercised warrants from a private financing in August.
 
The Series C warrants entitled the investor to purchase 1 million shares of BioForce’s common stock for $.50 per share. The firm’s shares closed at $.55 in Friday trade on the OTC Bulletin Board.
 
The proceeds from the exercise of the warrant are in addition to $500,000 BioForce received from the August financing.
 
“The warrant exercise proceeds provide us with the funds necessary to continue expansion of our sales and marketing efforts related to our Nano eNabler system, a device for the deposition and nanoscale manipulation of biomolecules,” said BioForce CEO Eric Henderson.
 
The firm also said the funds would support continued development of its ViriChip virus detection system.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more